DELCATH SYSTEMS, INC.

DELCATH SYSTEMS, INC. (DCTH) is a US-listed equity tracked across major market indices. Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

The company reports trailing twelve-month revenue of $7.77M and net loss of $1.07M. Key metrics include a return on equity of -0.9%, a debt-to-equity ratio of 0.11.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for DCTH to support both active traders and long-term investors.